The Molecular Oncology Almanac: Assertion Details

Assertion: Resistance to Nilotinib (in Chronic Myelogenous Leukemia)
Clinical evidence

Somatic Variant: ABL1 p.F359C (Missense)

Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.

Citations:

Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405

Assertion: Resistance to Nilotinib (in Chronic Myelogenous Leukemia) Clinical evidence

Clinical evidence

Assertion: Resistance to Nilotinib (in Chronic Myelogenous Leukemia)
Clinical evidence